Radiation-induced toxicity in cancer patients with low plasma fibronectin levels
-
Published:2010-11-11
Issue:1
Volume:10
Page:27-33
-
ISSN:1460-3969
-
Container-title:Journal of Radiotherapy in Practice
-
language:en
-
Short-container-title:J Radiother Pract
Author:
Baluna Roxana G.,Fuller Clifton D.,Eng Tony Y.,Ampil Federico L.,Thomas Charles R.
Abstract
AbstractThe present study was carried out to evaluate the levels of plasma fibronectin (Fn) in cancer patients undergoing radiation therapy (RT) in correlation with outcomes in terms of radiation toxicity. A total of 26 patients with lung and gastrointestinal (GI) cancer, treated with RT were enrolled in this study. Plasma Fn levels were determined before and following a course of RT. The Radiation Therapy Oncology Group (RTOG) criteria were used to determine the grade of RT toxicity. Statistical analysis utilised the nonparametric Mann–Whitney U-test as well as bivariate linear regression. Pre-RT Fn levels were significantly higher in cancer patients without toxicity (median ± SE) (485.0 ± 87 μg/ml) as compared with the levels of plasma Fn in patients with grade I–II RTOG acute toxicity (354.0 ± 74 μg/ml, p = 0.01). No significant difference in Fn levels was found in patients with grade I toxicity compared with patients with grade II toxicity. In addition, low baseline Fn levels (148 and 299 μg/ml) were observed in two lung cancer patients who developed symptomatic pneumonitis during the first 2 months after RT. These preliminary results suggest that low baseline Fn may have potential as a predictive marker for development of RT-induced toxicity.
Publisher
Cambridge University Press (CUP)
Subject
Oncology,Radiology, Nuclear Medicine and imaging
Reference35 articles.
1. Fibronectin and diabetes mellitus: the factors that influence its plasma concentrations and its usefulness as a marker of late complications;Simo;Med Clin,1999
2. Extracellular matrix and lung inflammation
3. Fibronectin expression in cancer tissues from patients undergoing radiation therapy;Nishioka;Histol Histopath,1993
4. Modifying Normal Tissue Damage Postirradiation
5. Significance of plasma transforming growth factor-β levels in radiotherapy for non–small-cell lung cancer